ADAM17 (a disintegrin and metalloproteinase domain 17), expressed on MDSCs, is likely to down-regulate L-selection on CD4+ and CD8+ T cells and prevent them to migrate to peripheral lymph nodes and tumor sites [5]. Here, CD4 is linked to neoplasm.